

References

L-195

1. Genetic testing for hereditary cancer syndromes. Available at: www.cancer.gov/about-cancer/causes-prevention/genetics/genetic-testing-fact-sheet.
2. Robson ME, Bradbury AR, Arun B, et al. American society of clinical oncology policy statement update: Genetic and genomic testing for cancer susceptibility. *J Clin Oncol*. 2015;33(31):3660–67. doi:10.1200/jco.2015.63.0996.
3. Raymond VM, Gray SW, Roychowdhury S, et al. Germline findings in tumor-only sequencing: Points to consider for clinicians and laboratories (Table 1). *J Natl Cancer Inst*. 2015;108(4):djv351. doi:10.1093/jnci/djv351.
4. Jones S, Anagnostou V, Lytle K, et al. Personalized genomic analyses for cancer mutation discovery and interpretation. *Sci Transl Med*. 2015;7(283):283ra53–283ra53. doi:10.1126/scitranslmed.aaa7161.
5. Schrader KA, Cheng DT, Joseph V, et al. Germline variants in targeted tumor sequencing using matched normal DNA. *JAMA Oncol*. 2016;2(1):104. doi:10.1001/jamaoncol.2015.5208.
6. Catenacci DVT, Amico AL, Nielsen SM, et al. Tumor genome analysis includes germline genome: Are we ready for surprises? *Int J Cancer*. 2014;136(7):1559–67. doi:10.1002/ijc.29128.
7. Green RC, Berg JS, Grody WW, et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. *Genetics in Medicine*. 2013;15(7):565–74. doi:10.1038/gim.2013.73.
8. Wolf SM, Annas GJ, Elias S. Patient autonomy and incidental findings in clinical genomics. *Science*. 2013;340(6136):1049–50. doi:10.1126/science.1239119.